The described invention provides a tumor
cell vaccine comprising genetically modified tumor
cell line of a particular
tumor type that stably expresses high levels of two or more immunomodulators. According to some embodiments, an immunogenic amount of the tumor
cell line variants may be selected for concomitant expression of two or more of recombinant membrane expressed IgG1, CD40L, TNF-alpha, as well as membrane and soluble forms of GM-CSF, and Flt-3L peptides that are effective to elicit an anti-tumor immune response compared to the parent unmodified tumor cell line as measured
in vitro by a one-way mixed
lymphocyte tumor reaction
assay using human
peripheral blood mononuclear cells and the genetically modified
allogeneic cell vaccine candidate. According to some embodiments, the tumor cell vaccine candidate will induce an immune response in the recipient
cancer patient that cross reacts with the patient's own (autologous)
tumor cells, the effects of which will be sufficient to result in enhanced anti-
tumor immunity contributing to the increased survival of a vaccinated patient cohort compared to a matched unvaccinated patient cohort.